Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/21/2017 04/24/2017 04/25/2017 04/26/2017 04/27/2017 Date
49.51(c) 50.3(c) 51.35(c) 54.02(c) 52.77(c) Last
664 849 447 465 475 453 808 194 454 042 Volume
-1.88% +1.60% +2.09% +5.20% -2.31% Change
More quotes
Financials ($)
Sales 2017 73,7 M
EBIT 2017 -459 M
Net income 2017 -460 M
Finance 2017 420 M
Yield 2017 -
Sales 2018 156 M
EBIT 2018 -420 M
Net income 2018 -416 M
Finance 2018 369 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 57,4x
EV / Sales2018 27,4x
Capitalization 4 649 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
04/27 ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing First Quarter 20..
04/27 MEDICINES : Alnylam, Medicines Company Announce Plans for Phase 3 Inclisiran Stu..
04/26 ALNYLAM PHARMACEUTICALS : Reports Final 24-Month Results from Phase 2 Open-Label..
04/26 ALNYLAM PHARMACEUTICALS : The Medicines Company and Alnylam Pharmaceuticals Anno..
04/20 ALNYLAM PHARMACEUTICALS : Reports Outline Nucleic Acids Research Study Findings ..
04/13 INVITAE : announces new partnership with Alnylam Pharmaceuticals to provide TTR ..
04/04 INVITAE : announces new partnership with Alnylam Pharmaceuticals to provide TTR ..
03/28 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 16th Annual Needham Healthc..
03/17 THE MEDICINES COMPANY : and Alnylam Pharmaceuticals Report Positive Final Result..
03/16 ALNYLAM PHARMACEUTICALS : Reports Outline Internet, Networks and Communications ..
More news
Sector news : Biotechnology & Medical Research - NEC
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
04/273 Things In Biotech You Should Learn Today: April 28, 2017  
04/26Mid-stage data support treatment benefit of Alnylam's patisiran in hATTR amyl.. 
04/26$MDCO (+4.4% pre) The Medicines Company Reports First-Quarter 2017 Financial .. 
04/26$ALNY (+7.1% pre) Medicines Co. $MDCO & Alnylam Announce Agreement w FDA .. 
04/26Medicines Co., Alnylam prepare to throw the dice on a late-stage effort to le..
5
More tweets
Qtime:22
News from SeekingAlpha
04/27 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 28, 2017
04/26 Mid-stage data support treatment benefit of Alnylam's patisiran in hATTR amyl..
04/26 Mid-stage study underway assessing Ra Pharma's RA101495 for PNH
04/26 The Medicines Co. gets FDA OK on late-stage development program for cholester..
04/17 Premarket analyst action - healthcare
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 65,1 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Michael P. Mason Treasurer & Principal Accounting Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICAL..37.15%4 649
INCYTE CORPORATION22.75%25 180
QUINTILES IMS HOLDINGS..8.68%19 586
LONZA GROUP AG19.57%12 278
CELLTRION, INC.--.--%9 719
SEATTLE GENETICS, INC.26.59%9 546
More Results